Pharmetheus offers consulting services focused on the application of quantitative approaches to support drug research, development and life-cycle decisions.
Our Communications
Latest news from Pharmetheus.
July 22, 2022
New publication on the relationship between tepotinib exposure, and efficacy and safety outcomes.
July 12, 2022
Pharmetheus back from PAGE 2022
July 8, 2022
Welcome Lénaïg Tanneau
July 6, 2022
Marblellous donations at Page 2022
July 1, 2022
Anti-drug antibody news
June 23, 2022
Pharmetheus at Page in Ljubljana, 2022
June 21, 2022
New overview articles related to subcutaneous administration
June 14, 2022
Introduction to new Board member Tomas Salmonson
June 8, 2022
Welcome Joakim Hellner!
May 31, 2022
Forest Plot Workshop in connection to ACOP 2022
July 22, 2022Forest plots, recommended by regulatory authorities and becoming a standard component of submission packages, can be used to efficiently summarize the impact of covariates on parameters from population models, as well as to illustrate the outcome in important patient subgroups.
Join our colleagues Niclas Jonsson and Joakim Nyberg for an on-site workshop on October 30, 2022, in connection with ACOP13 in Aurora, Colorado.
After this 1-day workshop, you will be fully familiar with Forest plots, from how to interpret them depending on assumptions and conditions set up, to how to create them with provided example R code.
Read more about the workshop here.
Register here through the ACOP website.
Services
Our services include quantitative analyses by scientists with extensive therapeutic area experience industry, academic and regularly settings.
Our team
Request our services
If you are interested in our services, please fill out the form below.
How we work
Our way of working, with traceability and accountability from data programming to report delivery, is well adapted to, and highly compatible with, current regulatory requirements.
Contact
About
Pharmetheus offers consulting services focused on the application of quantitative approaches to support drug development decisions..